Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss - Induced decrease in liver fat in humans

American Journal of Clinical Nutrition

Volumn 94, Issue 1, 2011, Pages 104-111

  Sevastianova, Ksenia ^a,b   Kotronen, Anna ^a,b   Gastaldelli, Amalia ^c   Perttilä, Julia ^a   Hakkarainen, Antti ^b   Lundbom, Jesper ^b   Suojanen, Laura ^b   Orho Melander, Marju ^d   Lundbom, Nina ^b   Ferrannini, Eleuterio ^e   Rissanen, Aila ^b   Olkkonen, Vesa M ^a   Yki Järvinen, Hannele ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ADIPONUTRIN; C PEPTIDE; FATTY ACID; GLYCEROL; INSULIN; PHOSPHOLIPASE; UNCLASSIFIED DRUG;

ADULT; AGE; ALLELE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; FATTY LIVER; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GLUCOSE METABOLISM; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPOLYSIS; LOW CARBOHYDRATE DIET; MALE; OXIDATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT REDUCTION;

3-HYDROXYBUTYRIC ACID; ADIPOSE TISSUE; ADULT; CALORIC RESTRICTION; DIETARY CARBOHYDRATES; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; GENETIC VARIATION; GLUCOSE; HUMANS; INSULIN; LIPASE; LIPOLYSIS; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; WEIGHT LOSS;

EID: 79959442292     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.012369     Document Type: Article

References (44)

1. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521-33, viii.
2. Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009;50:1035-42.
3. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
4. Kollerits B, Coassin S, Beckmann ND, et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genet 2009;18:4669-76.
5. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009;58:2616-23.
6. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009;52:1056-60.
7. Goran MI, Walker R, Le KA, et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010;59:3127-30.
8. Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010;53:335-8.
9. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903.
10. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111-6.
11. Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904-12.
12. Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1274-80.
13. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17.
14. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010;285:6706-15.
15. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-60.
16. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8.
17. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 2007;293:E1709-15.
18. Ryysy L, Häkkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58. (Pubitemid 30339990)
19. Sutinen J, Häkkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16:2183-93. (Pubitemid 35387273)
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
21. Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE. Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes 1986;35:1326-31. (Pubitemid 17199164)
22. Yki-Järvinen H, Young AA, Lamkin C, Foley JE. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest 1987;79:1713-9. (Pubitemid 17117278)
23. Yki-Järvinen H, Puhakainen I, Saloranta C, Groop L, Taskinen MR. Demonstration of a novel feedback mechanism between FFA oxidation from intracellular and intravascular sources. Am J Physiol 1991;260:E680-9.
24. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988;37:287-301. (Pubitemid 18080935)
25. Gastaldelli A, Coggan AR, Wolfe RR. Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol 1999;87:1813-22.
26. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
27. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008;134:1369-75. (Pubitemid 351615354)
28. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008;135:122-30. (Pubitemid 351899009)
29. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-13. (Pubitemid 19170111)
30. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991;72:96-107. (Pubitemid 21921662)
31. Frayn KN. Metabolic regulation. A human perspective. Oxford, United Kingdom: Blackwell Science, 2003.
32. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004;27:33-40. (Pubitemid 38196706)
33. Tiikkainen M, Bergholm R, Rissanen A, et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004;79:22-30. (Pubitemid 41132058)
34. Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010;52:1281-90.
35. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51. (Pubitemid 40629054)
36. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003;29:478-85. (Pubitemid 37474259)
37. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 2004;101:11245-50. (Pubitemid 39038332)
38. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-8.
39. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31. (Pubitemid 34496588)
40. Baulande S, Lasnier F, Lucas M, Pairault J. Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem 2001;276:33336-44.
41. Caimari A, Oliver P, Palou A. Regulation of adiponutrin expression by feeding conditions in rats is altered in the obese state. Obesity (Silver Spring) 2007;15:591-9. (Pubitemid 46643311)
42. Hoekstra M, Li Z, Kruijt JK, Van EM, Van Berkel TJ, Kuiper J. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol 2010;52:244-51.
43. Moldes M, Beauregard G, Faraj M, et al. Adiponutrin gene is regulated by insulin and glucose in human adipose tissue. Eur J Endocrinol 2006;155:461-8. (Pubitemid 44463953)
44. Polson DA, Thompson MP. Adiponutrin mRNA expression in white adipose tissue is rapidly induced by meal-feeding a high-sucrose diet. Biochem Biophys Res Commun 2003;301:261-6. (Pubitemid 36279231)